Published in Dig Dis Sci on July 26, 2006
HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch (2010) 2.72
Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer (2009) 1.82
Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol (2013) 1.62
HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature. J Cancer (2012) 1.54
MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells. Mol Cancer Ther (2012) 1.40
Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br J Cancer (2011) 1.34
HER2-positive gastric cancer. Gastric Cancer (2013) 1.32
Recent advances in gastrointestinal oncology--updates and insights from the 2009 annual meeting of the American society of clinical oncology. J Hematol Oncol (2010) 1.30
Survival of metastatic gastric cancer: Significance of age, sex and race/ethnicity. J Gastrointest Oncol (2011) 1.25
HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH). Histopathology (2011) 1.10
HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer. J Clin Pathol (2012) 1.09
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer (2014) 1.05
Her-2/neu testing and therapy in gastroesophageal adenocarcinoma. Patholog Res Int (2010) 1.05
Impact of HER-2 overexpression/amplification on the prognosis of gastric cancer patients undergoing resection: a single-center study of 1,036 patients. Oncologist (2011) 1.04
Low frequency of HER2 amplification and overexpression in early onset gastric cancer. Cell Oncol (Dordr) (2011) 1.02
Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients. BMC Cancer (2008) 1.02
HER2 expression and its clinicopathological features in resectable gastric cancer. Gastric Cancer (2012) 1.02
Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. Invest New Drugs (2010) 1.00
Molecular targeted agents for gastric and gastroesophageal junction cancer. Surg Today (2011) 0.97
Pathological complete response after neoadjuvant chemotherapy with trastuzumab-containing regimen in gastric cancer: a case report. J Hematol Oncol (2010) 0.95
Genome-wide gene copy number and expression analysis of primary gastric tumors and gastric cancer cell lines. BMC Cancer (2010) 0.95
Clinicopathological characteristics and predictive markers of early gastric cancer with recurrence. J Korean Med Sci (2009) 0.95
A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer. BMC Cancer (2009) 0.95
Engagement of overexpressed Her2 with GEP100 induces autonomous invasive activities and provides a biomarker for metastases of lung adenocarcinoma. PLoS One (2011) 0.94
Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics. Invest New Drugs (2009) 0.93
Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma. Virchows Arch (2014) 0.90
Prognostic implications of EGFR and HER-2 alteration assessed by immunohistochemistry and silver in situ hybridization in gastric cancer patients following curative resection. Gastric Cancer (2013) 0.90
Prognosis significance of HER-2/neu overexpression/amplification in Chinese patients with curatively resected gastric cancer after the ToGA clinical trial. World J Surg Oncol (2012) 0.90
Human epidermal growth factor receptor-2 expression in primary and metastatic gastric cancer. Int J Clin Oncol (2013) 0.89
ERBBs in the gastrointestinal tract: recent progress and new perspectives. Exp Cell Res (2008) 0.89
HER 2 Expression in Gastric and Gastro-esophageal Junction (GEJ) Adenocarcinomas. J Clin Diagn Res (2015) 0.87
HER-2 expression in immunohistochemistry has no prognostic significance in gastric cancer patients. ScientificWorldJournal (2012) 0.87
Molecular targeted agents for gastric cancer: a step forward towards personalized therapy. Cancers (Basel) (2013) 0.87
Evaluation of HER2-based biology in 1,006 cases of gastric cancer in a Japanese population. Gastric Cancer (2013) 0.87
The siRNA cocktail targeting VEGF and HER2 inhibition on the proliferation and induced apoptosis of gastric cancer cell. Mol Cell Biochem (2013) 0.86
HER2 expression in locally advanced gastric cancer with extensive lymph node (bulky N2 or paraaortic) metastasis (JCOG1005-A trial). Gastric Cancer (2014) 0.86
Retrospective analyses of cisplatin-based doublet combination chemotherapy in patients with advanced gastric cancer. BMC Cancer (2010) 0.86
HER-2 incidence in gastric cancer, its association with prognosis and clinicopathological parameters. Ulus Cerrahi Derg (2015) 0.85
A novel gene-protein assay for evaluating HER2 status in gastric cancer: simultaneous analyses of HER2 protein overexpression and gene amplification reveal intratumoral heterogeneity. Gastric Cancer (2014) 0.84
Is there any advantage to combined trastuzumab and chemotherapy in perioperative setting her 2neu positive localized gastric adenocarcinoma? World J Surg Oncol (2011) 0.84
HER2 Status in Premalignant, Early, and Advanced Neoplastic Lesions of the Stomach. Dis Markers (2015) 0.84
Human epidermal growth factor receptor 2 testing in gastric cancer: recommendations of an Asia-Pacific task force. Asia Pac J Clin Oncol (2014) 0.83
Metachronous liver and bone metastasis from small early gastric carcinoma without lymph node involvement: A case report. Mol Clin Oncol (2012) 0.83
Immunohistochemical molecular phenotypes of gastric cancer based on SOX2 and CDX2 predict patient outcome. BMC Cancer (2014) 0.83
Immunohistochemical biomarkers in gastric cancer research and management. Int J Surg Oncol (2012) 0.82
HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison. J Cancer Res Clin Oncol (2014) 0.80
Frequency of HER2/neu overexpression in adenocarcinoma of the gastrointestinal system. World J Gastroenterol (2014) 0.80
Recent advances in the HER2 targeted therapy of gastric cancer. World J Clin Cases (2015) 0.80
From molecular classification to targeted therapeutics: the changing face of systemic therapy in metastatic gastroesophageal cancer. Gastroenterol Res Pract (2015) 0.80
Significant intratumoral heterogeneity of human epidermal growth factor receptor 2 status in gastric cancer: A comparative study of immunohistochemistry, FISH, and dual-color in situ hybridization. Cancer Sci (2016) 0.79
Gastric biomarkers: a global review. World J Surg Oncol (2016) 0.79
Lauren classification and individualized chemotherapy in gastric cancer. Oncol Lett (2016) 0.79
Involvement of HER-2/neu and metastasis-related proteins in the development of ileal neuroendocrine tumors. Virchows Arch (2011) 0.79
Chemotherapy for gastric cancer patients - time for personalization in medicine? Contemp Oncol (Pozn) (2012) 0.79
HER2 expression in carcinomas of the true cardia (Siewert type II esophagogastric junction carcinoma). World J Surg (2014) 0.79
Immunohistochemical Analysis of p53, Ki-67, CD44, HER-2/neu Expression Patterns in Gastric Cancer, and Their Association with One Year Survival in North-West of Iran. Int J Hematol Oncol Stem Cell Res (2013) 0.79
HER2 Expression in Gastric and Gastroesophageal Cancer: Report from a Tertiary Care Hospital in North India. Indian J Surg (2013) 0.78
Clinical utility of HER2 assessed by immunohistochemistry in patients undergoing curative resection for gastric cancer. Onco Targets Ther (2016) 0.78
HER2 in gastric cancer: comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays. World J Gastroenterol (2013) 0.78
Detection of Her-2/neu expression in gastric cancer: Quantitative PCR versus immunohistochemistry. Exp Ther Med (2014) 0.78
Genomic profiling of submucosal-invasive gastric cancer by array-based comparative genomic hybridization. PLoS One (2011) 0.77
The advent of precision therapy in gastrointestinal malignancies: Targeting the human epidermal growth factor receptor family in colorectal and esophagogastric cancer. J Carcinog (2014) 0.76
HER2 testing in gastric cancer: An update. World J Gastroenterol (2016) 0.76
The Prognostic Significance of Her2-Neu Over expression in Gastric Carcinomas. Iran J Cancer Prev (2011) 0.76
Relative Prognostic Value of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Operable Oesophagogastric Cancer. ISRN Surg (2012) 0.76
Association of HER2 status with prognosis in gastric cancer patients undergoing R0 resection: A large-scale multicenter study in China. World J Gastroenterol (2016) 0.75
State of the art management of metastatic gastroesophageal cancer. Ann Transl Med (2015) 0.75
Targeted therapy for esophagogastric cancers: a review. Onco Targets Ther (2012) 0.75
The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature. World J Surg Oncol (2017) 0.75
HER2 testing in gastric cancer: results of a German expert meeting. J Cancer Res Clin Oncol (2017) 0.75
NanoString expression profiling identifies candidate biomarkers of RAD001 response in metastatic gastric cancer. ESMO Open (2016) 0.75
Profiling the prognosis of gastric cancer patients: is it worth correlating the survival with the clinical/pathological and molecular features of gastric cancers? ScientificWorldJournal (2013) 0.75
Study of C-MYC amplification and expression in Iranian gastric cancer samples using CISH and IHC methods. Adv Biomed Res (2015) 0.75
[The search for protein overexpression and HER2 gene amplification in gastric cancer by immunohistochemistry and in situ hybridization: experience of the CHU Hassan II of Fez]. Pan Afr Med J (2012) 0.75
The genomics and therapeutics of HER2-positive gastric cancer-from trastuzumab and beyond. J Gastrointest Oncol (2016) 0.75
Abstracts of New Developments in Hematology and Oncology in 2011. Guangzhou, China. December 25-26, 2011. J Hematol Oncol (2012) 0.75
Correlations of Human Epithelial Growth Factor Receptor 2 Overexpression with MUC2, MUC5AC, MUC6, p53, and Clinicopathological Characteristics in Gastric Cancer Patients with Curative Resection. Gastroenterol Res Pract (2015) 0.75
Epidemiologic Study of Human Epidermal Growth Factor Receptor 2 Expression in Advanced/Metastatic Gastric Cancer: an Assessment of Human Epidermal Growth Factor Receptor 2 Status in Tumor Tissue Samples of Gastric and Gastro-Esophageal Junction Cancer. J Gastric Cancer (2017) 0.75
[HER2 testing in gastric cancer : Results of a meeting of German experts]. Pathologe (2016) 0.75
Human Epidermal Growth Factor Receptor-2 in Sri Lankan Gastric Carcinoma Patients with Clinicopathological Association and Survival. Dig Dis Sci (2017) 0.75
Locoregional therapy with α-emitting trastuzumab against peritoneal metastasis of HER2-positive gastric cancer in mice. Cancer Sci (2017) 0.75
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 31.55
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol (2002) 13.81
Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science (1985) 9.12
Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J (1987) 4.33
The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science (1986) 3.74
Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol (2000) 3.56
Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene (1996) 3.33
Interpretation and quantification of immunostains. Am J Surg Pathol (2001) 2.82
Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res (1991) 1.92
Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer. Cancer (1995) 1.50
Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients. Cancer (1993) 1.50
Her-2/neu and breast cancer. Diagn Mol Pathol (2001) 1.38
Expression of ERBB2 in human gastric carcinomas: relationship between p185ERBB2 expression and the gene amplification. Cancer Res (1990) 1.38
Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer. Br J Cancer (1991) 1.25
c-erbB-2 oncogene product staining in gastric adenocarcinoma. An immunohistochemical study. J Pathol (1989) 1.22
A novel transcription factor, OB2-1, is required for overexpression of the proto-oncogene c-erbB-2 in mammary tumour lines. EMBO J (1993) 1.18
Relationship of C-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer. Cancer (1993) 1.13
Amplification of the c-erbB-2 (HER-2/neu) gene in gastric cancer cells. Detection by fluorescence in situ hybridization. Am J Pathol (1997) 1.10
Clinicopathological significance of c-erbB-2 protein expression in human gastric carcinoma. J Surg Oncol (1992) 1.07
Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells. Hum Pathol (1993) 1.06
c-erbB-2 proto-oncogene expression and its relationship to survival in gastric carcinoma: an immunohistochemical study on archival material. Int J Cancer (1991) 1.04
Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer. Cancer (1993) 1.04
Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185neu) in normal and transformed epithelial tissues of the digestive tract. Oncogene (1989) 1.02
Protein overexpression and gene amplification of c-erb B-2 in pulmonary carcinomas: a comparative immunohistochemical and fluorescence in situ hybridization study. Mod Pathol (2001) 1.02
Amplification of c-erbB-2 in gastric cancer: detection in formalin-fixed, paraffin-embedded tissue by fluorescence in situ hybridization. Lab Invest (1998) 1.01
The prognostic value of serum and immunohistochemical tumour markers in advanced gastric cancer. Eur J Cancer (1996) 0.98
Breast cancer in the 21st century: neu opportunities and neu challenges. Mod Pathol (2001) 0.96
An immunohistochemical study of c-erbB-2 protein in gastric carcinomas and lymph-node metastases: is the c-erbB-2 protein really a prognostic indicator? Int J Cancer (1993) 0.94
Long-term follow-up study of patients with gastric adenomas with malignant transformation. An immunohistochemical and histochemical analysis. Cancer (1994) 0.87
c-erbB-2 oncogene product expression and prognosis in gastric carcinoma. J Clin Pathol (1992) 0.83
Comparison of c-erbB-2 oncoprotein expression in tissue and serum of patients with stomach cancer. Tumour Biol (1994) 0.82
Prediction of the gastric cancer mortality in 2000 in Japan. Jpn J Cancer Res (1988) 0.82
c-erbB-2 expression is predictive for lymphatic spread of clinical gastric carcinoma. Hepatogastroenterology (1997) 0.78
Amplification of the c-erbB-2 gene detected by FISH in gastric cancers. Pathol Int (1997) 0.75
Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology (2008) 3.89
Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. Radiology (2006) 3.02
Dual and opposing roles of primary cilia in medulloblastoma development. Nat Med (2009) 2.73
A prospective nationwide study of drug-induced liver injury in Korea. Am J Gastroenterol (2012) 2.43
Laparoscopic-assisted distal gastrectomy versus open distal gastrectomy for advanced gastric cancer. Surg Endosc (2008) 2.26
Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J (2005) 2.17
Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage. Hepatology (2014) 2.14
The prognostic relevance of psammoma bodies and ultrasonographic intratumoral calcifications in papillary thyroid carcinoma. World J Surg (2013) 2.07
LIN28B promotes colon cancer progression and metastasis. Cancer Res (2011) 2.05
Outbreak of Mycobacterium massiliense infection associated with intramuscular injections. J Clin Microbiol (2007) 1.96
Hydrogen sulfide inhibits nitric oxide production and nuclear factor-kappaB via heme oxygenase-1 expression in RAW264.7 macrophages stimulated with lipopolysaccharide. Free Radic Biol Med (2006) 1.93
Carbon monoxide ameliorates chronic murine colitis through a heme oxygenase 1-dependent pathway. J Exp Med (2005) 1.90
Factors influencing the technical difficulty of endoscopic clearance of bile duct stones. Gastrointest Endosc (2007) 1.85
Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency. Proc Natl Acad Sci U S A (2012) 1.82
Altered macrophage function contributes to colitis in mice defective in the phosphoinositide-3 kinase subunit p110δ. Gastroenterology (2010) 1.80
Current Trends of the Incidence and Pathological Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Korea 2000-2009: Multicenter Study. Cancer Res Treat (2012) 1.76
Short-term outcomes of laparoscopic-assisted distal gastrectomy for gastric cancer during a surgeon's learning curve period. Surg Endosc (2009) 1.75
The serum response factor and a putative novel transcription factor regulate expression of the immediate-early gene Arc/Arg3.1 in neurons. J Neurosci (2009) 1.69
Why do African Americans get more colon cancer than Native Africans? J Nutr (2007) 1.64
Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea--a report from the Korean Breast Cancer Society. J Clin Oncol (2007) 1.62
Characteristics of metastasis in the breast from extramammary malignancies. J Surg Oncol (2010) 1.61
The efficacy of prophylactic low-molecular-weight heparin to prevent pulmonary thromboembolism in immediate breast reconstruction using the TRAM flap. Plast Reconstr Surg (2009) 1.61
A nationwide seroepidemiology of hepatitis C virus infection in South Korea. Liver Int (2013) 1.57
Complete biopsy resection of diminutive polyps. Endoscopy (2013) 1.57
Fatigue and depression in disease-free breast cancer survivors: prevalence, correlates, and association with quality of life. J Pain Symptom Manage (2008) 1.57
A pull out suture for transection of the posterior horn of the medial meniscus: using a posterior trans-septal portal. Knee Surg Sports Traumatol Arthrosc (2007) 1.54
Application of sonographic BI-RADS to synchronous breast nodules detected in patients with breast cancer. AJR Am J Roentgenol (2008) 1.51
Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. J Thorac Oncol (2009) 1.50
Primary tumor maximum standardized uptake value measured on 18F-fluorodeoxyglucose positron emission tomography-computed tomography is a prognostic value for survival in bile duct and gallbladder cancer. Korean J Gastroenterol (2013) 1.49
Novel electrical detection of label-free disease marker proteins using piezoresistive self-sensing micro-cantilevers. Biosens Bioelectron (2005) 1.49
PIK3CA mutations in in situ and invasive breast carcinomas. Cancer Res (2010) 1.49
Revision and update on clinical practice guideline for liver cirrhosis. Korean J Hepatol (2012) 1.47
Increased intestinal permeability as a predictor of bacterial infections in patients with decompensated liver cirrhosis and hemorrhage. J Gastroenterol Hepatol (2011) 1.47
[Usefulness of model for end-stage liver disease score for predicting mortality after intra-abdominal surgery in patients with liver cirrhosis in a single hospital]. Korean J Gastroenterol (2011) 1.46
Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis. J Leukoc Biol (2009) 1.45
Impact of nonalcoholic fatty liver disease on insulin resistance in relation to HbA1c levels in nondiabetic subjects. Am J Gastroenterol (2010) 1.42
Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma. Am J Surg (2005) 1.39
[C-reactive protein level and colorectal adenoma]. Korean J Gastroenterol (2008) 1.39
MicroRNA expression profiling outperforms mRNA expression profiling in formalin-fixed paraffin-embedded tissues. Int J Clin Exp Pathol (2009) 1.38
In-situ quantitative analysis of a prostate-specific antigen (PSA) using a nanomechanical PZT cantilever. Lab Chip (2004) 1.38
Simultaneous adrenal pheochromocytoma and sarcoidosis. South Med J (2009) 1.38
Abdominal obesity is an independent risk factor for erosive esophagitis in a Korean population. J Gastroenterol Hepatol (2007) 1.36
Clinical usefulness of 18F-FDG PET-CT for patients with gallbladder cancer and cholangiocarcinoma. J Gastroenterol (2009) 1.32
Prognostic significance of the metastatic lymph node ratio in patients with gastric cancer. World J Surg (2012) 1.31
An anti-inflammatory role for carbon monoxide and heme oxygenase-1 in chronic Th2-mediated murine colitis. J Immunol (2011) 1.31
Autophagy-related proteins, LC3 and Beclin-1, in placentas from pregnancies complicated by preeclampsia. Reprod Sci (2008) 1.29
Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men. J Gastroenterol Hepatol (2004) 1.28
Daily collection of self-reporting sleep disturbance data via a smartphone app in breast cancer patients receiving chemotherapy: a feasibility study. J Med Internet Res (2014) 1.28
The prognostic significance of tumor-associated stroma in invasive breast carcinoma. Tumour Biol (2012) 1.27
Microangiopathic hemolytic anemia as the first manifestation of metastatic signet ring cell carcinoma of unknown origin: a case report and review of literature. Korean J Lab Med (2011) 1.26
Pain after laparoscopic appendectomy: a comparison of transumbilical single-port and conventional laparoscopic surgery. J Korean Surg Soc (2012) 1.25
HER-2/neu overexpression is an independent prognostic factor in colorectal cancer. Int J Colorectal Dis (2006) 1.24